ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.
Compass Therapeutics Inc (NASDAQ:CMPX) Reports Wider Q2 2025 Loss, Shares Show Mixed Reaction Amid Clinical Progress Compass Therapeutics reports Q2 2025 results with a wider-than-expected loss but shows progress in clinical trials for oncology treatments. Market reacts mixedly.
Top movers in Wednesday's session Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Small Cap Compass Therapeutics Shares Positive Primary Goal Data From Pivotal Cancer Drug Study For Biliary Tract Cancer Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.
What's going on in today's after hours session After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Top 3 High-Momentum Companies Analysts Are Still Bullish On Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.
CMPX Stock Earnings: Compass Therapeutics Meets EPS for Q2 2024 CMPX stock results show that Compass Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024 CMPX stock results show that Compass Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
